Search clinical trials for: BMS-986205

Total 3151 results

Bristol-Myers Squibb

Completed

UNITY 2: A Study of an Investigational Treatment Regimen of DCV+ASV+BMS-791325 in a Fixed Dose Combination (the DCV 3DAA (Direct Acting Antiviral) Regimen) With or Without RBV for 12 Weeks for the Treatment of Chronic Hepatitis C Virus(HCV)Genotype 1 Infection in Subjects With Compensated Cirrhosis

Hepatitis C

United States, Australia, Canada, France
Bristol-Myers Squibb

Completed

A Study Measuring the Effectiveness of BMS-986256 Combined With Oral Contraceptive in Healthy Female Participants

Healthy Participants

United States
The Netherlands Cancer Institute
Bristol-Myers Squibb

Recruiting

Neoadjuvant Immune Checkpoint Inhibition and Novel IO Combinations in Early-stage Colon Cancer (NICHE)

Colon Carcinoma

Netherlands
Timothy Morgan, MD
Bristol-Myers Squibb; National Cancer Institute (NCI); VA Long Beach Healthcare...

Completed

Rapid Hepatitis C Elimination Trial- A Pilot Study of Daclatasvir/Asunaprevir/BMS-791325 With or Without Ribavirin To Treat Hepatitis C Virus (RHACE 1)

Hepatitis C

United States
Biohaven Pharmaceuticals, Inc.

Active, not recruiting

A Study to Evaluate the Efficacy and Safety of Taldefgrobep Alfa in Participants With Spinal Muscular Atrophy (RESILIENT)

Neuromuscular Diseases | Spinal Muscular Atrophy | SMA

United States, Netherlands, United Kingdom, Spain, Czechia, Belgium, Germany, Italy, Poland
RWTH Aachen University

Withdrawn

The Influence Cirrhosis of the Liver on the Coronary Re-stenosis (LTX- Stent Study)

Cirrhosis of the Liver | Re-stenosis
Dan Zandberg
Bristol-Myers Squibb

Active, not recruiting

Personalized Immunotherapy in Patients With Recurrent /Metastatic SCCHN That Have Progressed on Prior Immunotherapy

Squamous Cell Carcinoma of the Head and Neck

United States
Bristol-Myers Squibb

Completed

A Study of Brivanib (BMS-582664) in Patients With Liver Cancer and Mild, Moderate or Severe Liver Dysfunction

Carcinoma, Hepatocellular

United States, Spain
Catholic University of the Sacred Heart

Completed

A Meta-analysis of Drug Eluting Stents Versus Bare Metal Stents in Saphenous Vein Graft Disease

Saphenous Vein Graft Disease
Bristol-Myers Squibb

Completed

A Phase 3 Study of a Daclatasvir/Asunaprevir/BMS-791325 Fixed Dose Combination (FDC) in Subjects With Chronic Hepatitis C Genotype 1 (UNITY 4)

Hepatitis C Virus

Korea, Republic of, Taiwan, Russian Federation
University of Washington
National Cancer Institute (NCI); Prostate Cancer Foundation

Terminated

Cabozantinib in Men With Castration-Resistant Prostate Cancer

Recurrent Prostate Cancer | Castration-resistant Prostate Cancer | Stage III Prostate Cancer | Adenocarcinoma of the Prostate | Stage IV Prostate Cancer

United States
Bristol-Myers Squibb

Completed

Trial of BMS-690514 in Non-Small Cell Lung Cancer Subjects Who Have Been Treated With Gefitinib or Erlotinib and Are Genotypically EGFR Mutation Positive or Who Have Had a Prior Response

Non-Small-Cell Lung Carcinoma

Japan
Bristol-Myers Squibb

Completed

Safety Study of BMS-986202 in Healthy Subjects and to Treat Psoriasis

Psoriasis

Australia
Bristol-Myers Squibb

Completed

Safety Study of Pegylated Interferon Lambda Plus Single or 2 Direct Antiviral Agents With Ribavirin (D-LITE)

Hepatitis C

France, Germany, Italy, Japan, United States, Australia, Puerto Rico, Spain, New Zealand
Bristol-Myers Squibb

Completed

Multiple Ascending Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of BMS-986120 in Healthy Subjects and the Effects of Co-Administration of Midazolam and BMS-986120

Healthy Adult Volunteers

United States
H. Lee Moffitt Cancer Center and Research Institute
Bristol-Myers Squibb

Completed

CD40-L Blockade for Prevention of Acute Graft-Versus-Host Disease

GVHD | Graft-versus-host-disease | GVHD, Acute

United States
Bristol-Myers Squibb

Completed

The Effects Diflunisal on the Levels of BMS-986165 in Healthy Participants

Healthy Participants

United States
Sidney Kimmel Comprehensive Cancer Center at Johns...
Bristol-Myers Squibb

Recruiting

Feasibility and Efficacy of Perioperative Nivolumab With or Without Relatlimab for Patients With Potentially Resectable Hepatocellular Carcinoma (HCC)

Hepatocellular Carcinoma

United States
Bristol-Myers Squibb

Completed

An Anti-viral Combination Study With Japanese Hepatitis C Infection (HCV) Subject

Hepatitis C Infection

Japan
Bristol-Myers Squibb

Active, not recruiting

A Study of BMS-986416 With and Without Nivolumab in Select Solid Tumors

Advanced Solid Tumors

United States, Chile, Argentina, Belgium, Canada, Japan, Netherlands
Bristol-Myers Squibb

Completed

An Investigational Immunotherapy Study of BMS-986310 Administered Alone and in Combination With Nivolumab in Patients With Advanced Solid Tumors

Advanced Cancer

United States, Belgium, Canada
Bristol-Myers Squibb

Not yet recruiting

A Study to Assess the Drug Levels of Repotrectinib in Healthy Participants and Participants With Moderate and Severe Hepatic Impairment

Healthy Volunteers | Hepatic Impairment

United States
Juno Therapeutics, Inc., a Bristol-Myers Squibb...

Recruiting

Study of BMS-986393 a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma (QUINTESSENTIAL)

Multiple Myeloma

United States, Canada
Svelte Medical Systems Europe

Terminated

Acrobat Coronary Stent System Effectiveness European Study (ACES)

Coronary Artery Disease

Spain, France, Belgium
Bristol-Myers Squibb

Completed

Determine the Pharmacokinetics and Safety of Brivanib in Chinese Subjects With Advanced Primary Liver Cancer (Hepatocellular Carcinoma: HCC)

Hepatocellular Carcinoma

China
Meridian Bioscience, Inc.
Bristol-Myers Squibb

Completed

Companion Protocol for ¹³C-Methacetin Breath Tests in BMS: NCT03486899, NCT03486912 Referenced Trials

NASH - Nonalcoholic Steatohepatitis

United States
Bristol-Myers Squibb

Completed

A Study of Experimental Medication BMS-986036 in Adults With Nonalcoholic Steatohepatitis (NASH) and Liver Cirrhosis (FALCON 2)

Nonalcoholic Steatohepatitis | Liver Fibrosis | Nonalcoholic Fatty Liver Disease (NAFLD) | Hepatic Cirrhosis

United States, Japan
Southwest Oncology Group
National Cancer Institute (NCI)

Completed

S0355 Ixabepilone in Treating Patients With Advanced Solid Tumors or Lymphomas and Liver Dysfunction

Lymphoma | Small Intestine Cancer | Unspecified Adult Solid Tumor, Protocol Specific

United States
Bristol-Myers Squibb

Terminated

Study of BMS-582664 in Combination With Either FOLFIRI or FOLFOX for Gastrointestinal (GI) Malignancies

Gastrointestinal Neoplasms

United States
Bristol-Myers Squibb

Completed

Pharmacokinetics and Metabolism of Radiolabeled BMS-690514 in Healthy Male Subjects

Cancer

Switzerland
Bristol-Myers Squibb

Completed

Clinical Trial of the Combination of Intravenous Alvespimycin (KOS-1022), Trastuzumab With or Without Paclitaxel in Patients With Advanced Solid Tumor Malignancies or Her2 Positive Metastatic Breast Cancer Who Have Previously Failed Trastuzumab Therapy

Breast Cancer | Solid Tumor

United States
Emory University
National Cancer Institute (NCI); National Institutes of Health (NIH); Exelixis

Active, not recruiting

Neoadjuvant Cabozantinib in Treating Patients With Locally Advanced Kidney Cancer

Renal Cell Carcinoma | Clear Cell Renal Cell Carcinoma | Stage III Renal Cell Cancer AJCC v8

United States
Bristol-Myers Squibb

Completed

A Study to Determine the Safety, Drug Levels and Drug Effects of BMS-986196 and Food and Formulation Effects on Relative Absorption Healthy Participants

Healthy Participants

United States
Bristol-Myers Squibb

Completed

A Study of Experimental Medication BMS-986036 in Adults With Nonalcoholic Steatohepatitis (NASH) and Stage 3 Liver Fibrosis (FALCON 1)

Nonalcoholic Steatohepatitis | Liver Fibrosis | Nonalcoholic Fatty Liver Disease (NAFLD)

United States, Japan
Bristol-Myers Squibb

Terminated

A Phase 1/2 Study of Epofolate (BMS-753493) in Subjects With Advanced Cancer (Schedule 2)

Advanced Solid Tumors

United States, Canada, United Kingdom
Bristol-Myers Squibb

Completed

Clinical Trial of Continuing Treatment for Patients Who Have Participated on a Prior Protocol Investigating Tanespimycin

Advanced Malignancies

United States
Bristol-Myers Squibb

Completed

Study to Evaluate the Safety, Pharmacokinetics and Target Engagement of BMS-986142 in Healthy Subjects

Healthy Adult

United States
Bristol-Myers Squibb

Completed

Multiple Ascending Dose Study of BMS-820132 in Patients With Type 2 Diabetes

Type 2 Diabetes

United States
Bristol-Myers Squibb

Completed

Safety Study of BMS-903452 in Healthy Subjects (Panel 1-7) & Relative Bioavailability of the Crystalline and Amorphous Forms of BMS-903452 [Panels 4, 6, 11 & 12(Part A)], and Subjects With Type 2 Diabetes Mellitus (Part B)

Diabetes

United States
Bristol-Myers Squibb

Completed

Multiple-Dose Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of BMS-779788 in Healthy Subjects

Atherosclerosis

Australia
Bristol-Myers Squibb

Completed

Multiple-Ascending Dose Study

Depression

Sweden
Bristol-Myers Squibb

Completed

Multiple Dose Study In Treatment Naive Subjects Infected With Hepatitis C Virus

Chronic Hepatitis C

United States
Bristol-Myers Squibb

Completed

A Phase I Study to Determine Absorption, Distribution, Metabolism, and Elimination of a Single Radiolabeled Dose of Brivanib (BMS-582664)

Tumors

United States
Bristol-Myers Squibb

Recruiting

A Study of BMS-986449 With and Without Nivolumab in Participants With Advanced Solid Tumors

Advanced Solid Tumors

Spain, United States, France, Italy, Belgium, Netherlands
Bristol-Myers Squibb

Completed

An Investigational Immuno-therapy Study of Experimental Medication BMS-986179 Given Alone and in Combination With Nivolumab

Malignant Solid Tumor

United States, France, Italy, Australia, Canada, Germany, Netherlands
Bristol-Myers Squibb

Terminated

A Study of the Safety and Tolerability of BMS-986183 in Patients With Liver Cancer

Hepatocellular Carcinoma

Canada, Singapore, Korea, Republic of, Taiwan
Bristol-Myers Squibb

Completed

Drug-Drug Interaction Study in Healthy Subjects

Hepatitis C

United States
Bristol-Myers Squibb

Completed

Effectiveness and Safety of BMS-986165 Compared to Placebo and Active Comparator in Participants With Psoriasis (POETYK-PSO-1)

Psoriasis

China, Korea, Republic of, Spain, United States, United Kingdom, Canada, Russian Federation, Japan, Germany, Poland, Taiwan
Bristol-Myers Squibb

Completed

Study of BMS-986158 in Subjects With Select Advanced Cancers (BET)

Advanced Tumors

United States, France, Australia, Spain, Canada
Bristol-Myers Squibb

Terminated

An Investigational Immuno-therapy Study to Determine the Safety of Urelumab Given in Combination With Nivolumab in Solid Tumors and B-cell Non-Hodgkin's Lymphoma

Advanced Solid Tumors | Advanced B-cell NHL

United States, France, Spain, Germany

3

Subscribe